Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Sees Revenues Dwindle, Profits Turn to Losses in Q1; Downturn Termed Temporary

NEW YORK, May 5 (GenomeWeb News) - Third Wave Technologies today reported a sharp downturn in revenues and a net loss for the first quarter of 2005.

 

Revenues for the period totaled $7.1 million, down from $15.3 million during the same quarter in 2004. Third wave attributed this shortfall to a lack of research revenue, a delay by one of its suppliers, and "performance issues" with an instrument from Roche that is required for Third Wave's HCV genotyping analyte-specific reagents.

 

"As expected, our research revenue will continue to be lower than it has been historically," CEO John Puisis said in a company statement. "We believe the temporary delays that impacted our molecular diagnostic revenue in the first quarter have been remedied."

 

Research and development costs stayed flat at $2.5 million compared to $2.7 million during last year's first quarter.

 

Third Wave recorded a net loss of $4.4 million, or $.11 per share, compared to net earnings of $2.8 million, or $.07 per share, during the same quarter last year.

 

As of March 31, Third Wave had $64.5 million in cash, cash equivalents, and short-term investments.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.